Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Oncology

Standard of Care: Chemotherapy, Targeted Pills, and Immunotherapy

At a Glance

Treatment for Acute Lymphoblastic Leukemia (ALL) uses a personalized combination of pediatric-inspired chemotherapy, targeted pills for specific genetic markers like Ph+, and advanced immunotherapy. Treatment is tailored to your leukemia type to maximize disease control and manage side effects.

The treatment for Acute Lymphoblastic Leukemia (ALL) has evolved rapidly. Today, doctors use a combination of traditional chemotherapy, “targeted” drugs that home in on specific genetic glitches, and “immunotherapy” that uses your own immune system to fight the cancer [1][2].

The Gold Standard: Pediatric-Inspired Regimens (PIRs)

For many years, adults were treated with one set of drugs and children with another. However, research discovered that Adolescents and Young Adults (AYAs) and even many adults have much better survival rates when treated with the more intensive protocols originally designed for children [1][3].

  • Why they work: These regimens prioritize higher doses of specific drugs like asparaginase and vincristine [3][4].
  • The Result: Patients treated with these “pediatric-inspired” protocols often see better disease control and fewer relapses than those on traditional adult-focused regimens like “hyper-CVAD” [5][6].

Targeted Therapy for Ph+ ALL

If your leukemia is Philadelphia chromosome-positive (Ph+), your treatment will include a Tyrosine Kinase Inhibitor (TKI) [7]. These are “smart” drugs that specifically block the signal telling the cancer cells to grow.

  • Generations of TKIs: You may start with dasatinib or a newer, more potent drug like ponatinib [7][8].
  • Fewer Side Effects: Using these targeted pills often allows doctors to reduce the amount of harsh, traditional chemotherapy needed, making the treatment easier on your body while still being highly effective [9][10].

The Rise of Immunotherapy

Immunotherapy represents a major breakthrough in ALL. Instead of poisoning the cancer cells, these drugs help your immune system find and destroy them [2][11].

  • Blinatumomab: This drug acts like a “matchmaker.” It has two ends: one grabs a leukemia cell and the other grabs a healthy T-cell (an immune soldier), forcing them together so the immune cell can kill the cancer [12]. It is often used to clear away Minimal Residual Disease (MRD) [13][14].
  • CAR T-Cell Therapy: This is a high-tech process where your own immune cells are removed, “reprogrammed” in a lab to hunt leukemia, and then put back into your body [15]. It is usually reserved for cancer that has come back (relapsed) or hasn’t responded to other treatments [16][14].

Stem Cell / Bone Marrow Transplant

For some patients—particularly adults, those with high-risk genetic markers, or those whose leukemia returns—a Stem Cell Transplant (or Bone Marrow Transplant) may be recommended [17].

  • What it is: This procedure involves giving very high doses of chemotherapy (and sometimes radiation) to completely destroy the diseased bone marrow. Then, healthy stem cells from a donor (an “allogeneic” transplant) are infused into your blood to rebuild a new, healthy immune system [18].
  • The Goal: The new immune system can often recognize and attack any remaining leukemia cells, offering a potential cure for high-risk ALL [19].

Managing Complex Side Effects

Because these treatments are intensive, they come with specific “side effects” that your team will monitor closely:

  • Immediate Quality of Life: Intensive chemotherapy often causes complete hair loss (alopecia) and can lead to painful mouth sores (mucositis). Your care team has specialized mouthwashes and pain management strategies to help you through this [4].
  • Organ Toxicity: The core drug asparaginase can sometimes cause the pancreas to become inflamed (pancreatitis) or cause the liver to work less effectively (hepatotoxicity) [4][20]. It can also increase the risk of blood clots (thrombosis) [21][22].
  • Close Monitoring: Your team will perform regular blood tests to check your liver enzymes and triglyceride levels [23][24]. If you experience severe abdominal pain, swelling in a leg, or shortness of breath, you must notify your doctor immediately [25][21].

By combining these different tools—chemo, targeted pills, stem cells, and immunotherapy—doctors can now create a “precision” plan tailored to your specific type of leukemia [26][10].

Common questions in this guide

What is a pediatric-inspired regimen for ALL?
A pediatric-inspired regimen is an intensive chemotherapy protocol originally designed for children that is now effectively used for younger adults. It prioritizes higher doses of specific drugs like asparaginase and vincristine, which has been shown to improve survival rates and reduce relapses.
How is Philadelphia chromosome-positive (Ph+) ALL treated?
If your leukemia is Ph-positive, your treatment will include targeted pills called Tyrosine Kinase Inhibitors (TKIs), such as dasatinib or ponatinib. These drugs block the signals that tell cancer cells to grow and often allow doctors to use less of the harsh traditional chemotherapy.
How does immunotherapy work for leukemia?
Immunotherapy helps your own immune system fight the cancer. For example, the drug blinatumomab connects a leukemia cell directly to a healthy immune T-cell, forcing them together so your immune system can recognize and destroy the cancer.
When is a stem cell transplant recommended for ALL?
A stem cell transplant is often recommended for adults, patients with high-risk genetic markers, or those whose leukemia has relapsed. The procedure uses high doses of chemotherapy to destroy the diseased bone marrow before infusing healthy donor stem cells to rebuild a new immune system.
What are the potential side effects of asparaginase?
Asparaginase is a core drug in ALL treatment that can cause inflammation of the pancreas (pancreatitis), liver toxicity, and an increased risk of blood clots. Your care team will monitor you closely with regular blood tests to check your liver enzymes and triglyceride levels.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why is a 'pediatric-inspired' regimen recommended for my age group, and how does it differ from traditional adult chemotherapy?
  2. 2.If my leukemia is Ph-positive, which generation of TKI (e.g., dasatinib or ponatinib) will we use first?
  3. 3.Are we planning to use blinatumomab or other immunotherapies to reach an MRD-negative status?
  4. 4.At what point would we consider a stem cell transplant versus continuing with chemotherapy and targeted drugs?
  5. 5.What is the monitoring plan for asparaginase side effects like pancreatitis or blood clots?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study.

    Zalapa-Soto J, Rios-Olais FA, Chacón-Rangel LC, et al.

    European journal of haematology 2025; (114(5)):793-801 doi:10.1111/ejh.14381.

    PMID: 39777938
  2. 2

    KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

    Shah BD, Ghobadi A, Oluwole OO, et al.

    Lancet (London, England) 2021; (398(10299)):491-502 doi:10.1016/S0140-6736(21)01222-8.

    PMID: 34097852
  3. 3

    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.

    Siegel SE, Advani A, Seibel N, et al.

    American journal of hematology 2018; (93(10)):1254-1266 doi:10.1002/ajh.25229.

    PMID: 30058716
  4. 4

    Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.

    Schulte R, Hinson A, Huynh V, et al.

    Cancer medicine 2021; (10(21)):7551-7560 doi:10.1002/cam4.4281.

    PMID: 34528411
  5. 5

    A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.

    Ribera JM, Morgades M, Montesinos P, et al.

    Cancer medicine 2020; (9(7)):2317-2329 doi:10.1002/cam4.2814.

    PMID: 32022463
  6. 6

    Acute lymphoblastic leukemia in young adults: which up-front treatment?.

    Molina JC, Rotz S

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):573-580 doi:10.1182/hematology.2023000510.

    PMID: 38066875
  7. 7

    Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

    Ribera JM, Morgades M, Ribera J, et al.

    HemaSphere 2024; (8(4)):e67 doi:10.1002/hem3.67.

    PMID: 38566805
  8. 8

    Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.

    Ribera JM, Prawitz T, Freitag A, et al.

    Advances in therapy 2023; (40(7)):3087-3103 doi:10.1007/s12325-023-02497-y.

    PMID: 37208556
  9. 9

    Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.

    Shahzad M, Hussain A, Tariq E, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(3)):178-187 doi:10.1016/j.clml.2023.01.002.

    PMID: 36682989
  10. 10

    Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?

    Sohn SK, Lee JM, Jang Y, et al.

    Expert review of hematology 2024; (17(7)):353-359 doi:10.1080/17474086.2024.2357273.

    PMID: 38755522
  11. 11

    Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

    Stein AS, Kantarjian H, Gökbuget N, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(8)):1498-1504 doi:10.1016/j.bbmt.2019.04.010.

    PMID: 31002989
  12. 12

    Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

    Martinelli G, Boissel N, Chevallier P, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(16)):1795-1802 doi:10.1200/JCO.2016.69.3531.

    PMID: 28355115
  13. 13

    Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

    Couturier MA, Thomas X, Raffoux E, et al.

    Leukemia & lymphoma 2021; (62(3)):620-629 doi:10.1080/10428194.2020.1844198.

    PMID: 33153370
  14. 14

    Long-Term Remission in T315I+ Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Blinatumomab and Allogeneic Stem Cell Transplantation: Two Case Studies.

    Huang Z, Zhang Y, Chen J, et al.

    The American journal of case reports 2024; (25()):e944956 doi:10.12659/AJCR.944956.

    PMID: 39099157
  15. 15

    Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation.

    Yang F, Yang X, Bao X, et al.

    Leukemia & lymphoma 2020; (61(2)):429-436 doi:10.1080/10428194.2019.1663417.

    PMID: 31512942
  16. 16

    Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.

    El Chaer F, Holtzman NG, Sausville EA, et al.

    Acta haematologica 2019; (141(2)):107-110 doi:10.1159/000495558.

    PMID: 30695783
  17. 17

    IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.

    Ruiz-Delgado GJ, Cantero-Fortiz Y, León-Peña AA, et al.

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2016; (68(4)):210-4.

    PMID: 27623040
  18. 18

    MYC degradation via AURKB inhibition: a new brake in the path to T-ALL.

    Zhang W, Pear WS

    Blood science (Baltimore, Md.) 2020; (2(2)):68-69 doi:10.1097/BS9.0000000000000046.

    PMID: 35402818
  19. 19

    Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.

    Schumich A, Maurer-Granofszky M, Attarbaschi A, et al.

    Pediatric blood & cancer 2019; (66(5)):e27590 doi:10.1002/pbc.27590.

    PMID: 30561169
  20. 20

    Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.

    Chen J, Ngo D, Aldoss I, et al.

    Leukemia & lymphoma 2019; (60(5)):1187-1192 doi:10.1080/10428194.2018.1519811.

    PMID: 30322332
  21. 21

    Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.

    Underwood B, Zhao Q, Walker AR, et al.

    International journal of hematologic oncology 2020; (9(3)):IJH28 doi:10.2217/ijh-2020-0009.

    PMID: 33014332
  22. 22

    TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.

    Klaassen ILM, Lauw MN, van de Wetering MD, et al.

    BMC pediatrics 2017; (17(1)):122 doi:10.1186/s12887-017-0877-x.

    PMID: 28486976
  23. 23

    SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.

    Aldoss I, Pourhassan H, Douer D

    Clinical lymphoma, myeloma & leukemia 2022; (22(11)):787-794 doi:10.1016/j.clml.2022.08.009.

    PMID: 36114134
  24. 24

    Safety of re-challenging adults with acute lymphoblastic leukemia with PEG-asparaginase-induced severe hypertriglyceridemia when treated with a pediatric-inspired regimen.

    Al Nabhani I, Andrews C, Sibai J, et al.

    EJHaem 2023; (4(1)):232-235 doi:10.1002/jha2.607.

    PMID: 36819167
  25. 25

    Acute pancreatitis in children with acute lymphoblastic leukemia correlates with L-asparaginase dose intensity.

    Chen CB, Chang HH, Chou SW, et al.

    Pediatric research 2022; (92(2)):459-465 doi:10.1038/s41390-021-01796-w.

    PMID: 34718353
  26. 26

    Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.

    Chiaretti S, Messina M, Della Starza I, et al.

    Haematologica 2021; (106(6)):1559-1568 doi:10.3324/haematol.2020.247973.

    PMID: 32467145

This page explains standard treatments for acute lymphoblastic leukemia for educational purposes only. Always discuss your specific treatment plan, drug choices, and side effect management with your oncologist.

Get notified when new evidence is published on Acute lymphoblastic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.